Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection

Jesper Waldenström; Johan Westin; Kristina Nyström; Peer Christensen; Olav Dalgard; Martti Färkkilä; Karin Lindahl; Staffan Nilsson; Gunnar Norkrans; Henrik Krarup; Hans Norrgren; Mads Rauning Buhl; Stephan Stenmark; Martin Lagging

doi:10.1371/journal.pone.0155142

Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection

Jesper Waldenström, Johan Westin, Kristina Nyström, Peer Christensen, Olav Dalgard, Martti Färkkilä, Karin Lindahl, Staffan Nilsson, Gunnar Norkrans, Henrik Krarup, Hans Norrgren, Mads Rauning Buhl, Stephan Stenmark, Martin Lagging

Infection Medicine (BMC)

Research output: Contribution to journal › Article › peer-review

Abstract

In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log₁₀ IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log₁₀ IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P

Original language	English
Article number	e0155142
Journal	PLoS ONE
Volume	11
Issue number	5
DOIs	https://doi.org/10.1371/journal.pone.0155142
Publication status	Published - 2016

Subject classification (UKÄ)

Infectious Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0155142

Cite this

Waldenström, J., Westin, J., Nyström, K., Christensen, P., Dalgard, O., Färkkilä, M., Lindahl, K., Nilsson, S., Norkrans, G., Krarup, H., Norrgren, H., Buhl, M. R., Stenmark, S., & Lagging, M. (2016). Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection. PLoS ONE, 11(5), Article e0155142. https://doi.org/10.1371/journal.pone.0155142

@article{8f34c092de60485e96e270ee0cf965e1,

title = "Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection",

abstract = "In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-na{\"i}ve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log10 IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log10 IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P",

author = "Jesper Waldenstr{\"o}m and Johan Westin and Kristina Nystr{\"o}m and Peer Christensen and Olav Dalgard and Martti F{\"a}rkkil{\"a} and Karin Lindahl and Staffan Nilsson and Gunnar Norkrans and Henrik Krarup and Hans Norrgren and Buhl, {Mads Rauning} and Stephan Stenmark and Martin Lagging",

year = "2016",

doi = "10.1371/journal.pone.0155142",

language = "English",

volume = "11",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science (PLoS)",

number = "5",

}

Waldenström, J, Westin, J, Nyström, K, Christensen, P, Dalgard, O, Färkkilä, M, Lindahl, K, Nilsson, S, Norkrans, G, Krarup, H, Norrgren, H, Buhl, MR, Stenmark, S & Lagging, M 2016, 'Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection', PLoS ONE, vol. 11, no. 5, e0155142. https://doi.org/10.1371/journal.pone.0155142

TY - JOUR

T1 - Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection

AU - Waldenström, Jesper

AU - Westin, Johan

AU - Nyström, Kristina

AU - Christensen, Peer

AU - Dalgard, Olav

AU - Färkkilä, Martti

AU - Lindahl, Karin

AU - Nilsson, Staffan

AU - Norkrans, Gunnar

AU - Krarup, Henrik

AU - Norrgren, Hans

AU - Buhl, Mads Rauning

AU - Stenmark, Stephan

AU - Lagging, Martin

PY - 2016

Y1 - 2016

N2 - In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log10 IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log10 IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P

AB - In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log10 IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log10 IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P

UR - http://www.scopus.com/inward/record.url?scp=84969796323&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0155142

DO - 10.1371/journal.pone.0155142

M3 - Article

C2 - 27167219

AN - SCOPUS:84969796323

SN - 1932-6203

VL - 11

JO - PLoS ONE

JF - PLoS ONE

IS - 5

M1 - e0155142

ER -

Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this